ReviewNeuropsychiatric disease and treatment2025
Anxiolytic Effects of Natural Products: Pathological Mechanisms, Molecular Targets, Therapeutic Prospects.
Review in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ethnobotanical Uses and Phytochemical, Pharmacological, Behavioral, and Toxicological Effects ofMolecules (Basel, Switzerland) · 2026Review
- Wild Flora Species from Romania with Anxiolytic and Antidepressant Potential: A Global Perspective-Narrative Review.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety disorders are complex neuropsychiatric conditions with incompletely understood mechanisms, which hinders the development of targeted therapies. Natural products have attracted attention as promising anxiolytic candidates due to their multi-component nature, synergistic effects, and ability to modulate multiple molecular targets and signaling pathways. However, a systematic integration of anxiety pathology with the mechanisms of natural products is still lacking. This review summarizes recent advances in the molecular and cellular basis of anxiety and explores how natural products (such as flavonoids, terpenoids, and alkaloids) interact with key genes, receptors, and intracellular signaling pathways. It also addresses current research limitations, including insufficient depth of mechanistic studies, lack of standardized models, and challenges in clinical translation. By synthesizing mechanistic and therapeutic evidence, this work aims to support the development of effective, evidence-based natural anxiolytics with improved clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.